HMGB1 related pathways in epilepsy
Küçük Resim Yok
Tarih
2022
Dergi Başlığı
Dergi ISSN
Cilt Başlığı
Yayıncı
Nova Science Publishers, Inc.
Erişim Hakkı
info:eu-repo/semantics/closedAccess
Özet
Epilepsy is one of the most common neurological illnesses, affecting an estimated 70 million individuals worldwide. A mechanistic approach to discovering crucial pathogenic brain abnormalities driving seizure onset, recurrence, and advancement is critical for generating novel and rational treatment methods that may modify or prevent disease progression. In this context, an increasing body of evidence suggests that neuroinflammation plays a role in drug-resistant epilepsies. The high mobility group box 1 (HMGB1) protein, a key regulator of neuroinflammation, has been associated with several neurological disorders, including epilepsy. Increased levels of HMGB1, one of the most prominent pro-inflammatory cytokines, have been linked to seizure length, recurrence, and epilepsy development. Therefore, HMGB1 has attracted a lot of attention and has been developed quickly. According to clinical and experimental data, HMGB1 isoforms may serve as neurobiological biomarkers for epileptogenesis and drug-resistant epilepsy. These novel findings suggest that the HMGB1 system could be targeted to prevent seizure generation and provide therapeutically relevant prognostic markers that can also predict a patient's response to therapy. This section will recap epileptogenesis theory and examine the relationships between epilepsy and neuroinflammatory pathways using experimental and clinical evidence. © 2023 by Nova Science Publishers, Inc. All rights reserved.
Açıklama
Anahtar Kelimeler
Epilepsy, HMGB1, Neuroinflammation
Kaynak
HMGB1: Functions, Inhibitors and Clinical Significance
WoS Q Değeri
Scopus Q Değeri
N/A
